NVCN - Neovasc expands direct sales operations to include the UK
- Neovasc ( NASDAQ: NVCN ) has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022 .
- The company has hired its first two direct employees in England and plans future growth in the sales team as the commercial requirements increase.
- The expansion is driven by NICE guidelines and enhanced reimbursement for the Neovasc Reducer™.
- “We are now poised to provide even deeper support with a full-time dedicated team in the U.K. and intend to continue to invest in clinical research and field personnel to support patients, physicians, and hospitals.” said Fred Colen, Neovasc President and CEO.
For further details see:
Neovasc expands direct sales operations to include the UK